Expanded Access to NanoPac

NCT03756311 | Unknown

• 1 other identifier: NANOPAC-EA
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

NanOlogy may consider offering expanded access to NanoPac for patients who do not meet the enrollment criteria of clinical trials in progress.

Conditions

Locally Advanced Pancreatic Carcinoma; Prostate Cancer; Lung Cancer

Interventions

NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension DRUG

Also known as: Paclitaxel

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Sponsors & Collaborators

• NanOlogy, LLC: lead

MeSH Terms

Conditions

Prostatic Neoplasms; Lung Neoplasms

Interventions

Powders; Suspensions; Paclitaxel

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Dosage Forms; Pharmaceutical Preparations; Colloids; Complex Mixtures; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 26, 2018
• First Posted: November 28, 2018
• Last Updated: January 23, 2026

Record last verified: 2026-01